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Abstract
Introduction: Treatment of acute lung injury (ALI) remains an unsolved problem in intensive care medicine. As simvastatin
exerts protective effects in inflammatory diseases we explored its effects on development of ALI and due to the importance
of neutrophils in ALI also on neutrophil effector functions.
Methods: C57Bl/6 mice were exposed to aerosolized LPS (500 mg/ml) for 30 min. The count of alveolar, interstitial, and
intravasal neutrophils were assessed 4 h later by flow cytometry. Lung permeability changes were assessed by FITC-dextran
clearance and albumin content in the BAL fluid. In vitro, we analyzed the effect of simvastatin on neutrophil adhesion,
degranulation, apoptosis, and formation of reactive oxygen species. To monitor effects of simvastatin on bacterial clearance
we performed phagocytosis and bacterial killing studies in vitro as well as sepsis experiments in mice.
Results: Simvastatin treatment before and after onset of ALI reduces neutrophil influx into the lung as well as lung
permeability indicating the protective role of simvastatin in ALI. Moreover, simvastatin reduces the formation of ROS species
and adhesion of neutrophils without affecting apoptosis, bacterial phagocytosis and bacterial clearance.
Conclusion: Simvastatin reduces recruitment and activation of neutrophils hereby protecting from LPS-induced ALI. Our
results imply a potential role for statins in the management of ALI.
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Introduction
Acute lung injury (ALI) is a life-threatening disease with an age-
adjusted incidence of 86.2 per 100.000 person-years [1]. Despite
all innovations in intensive care medicine, the mortality of ALI
remains up to 40%. ALI is characterized by an increased
permeability of the alveolar-capillary barrier resulting in lung
edema with protein-rich fluid consequently leading to impairment
of arterial oxygenation. A major cause for development of ALI is
sepsis, wherein Gram-negative bacteria are a prominent cause [2].
LPS inhalation mimics human Gram-negative ALI, inducing
neutrophil recruitment, pulmonary edema and finally impairment
of gas exchange [3].
Recruitment of neutrophils is a key event in development of ALI
resulting in plasma leakage and deterioration of oxygenation [1,4].
The importance of neutrophils in ALI is affirmed by studies where
lung injury is abolished or reversed by depletion of neutrophils
[5,6]. Granule proteins from activated neutrophils, e.g. azurocidin
and a-defensins, alter directly permeability changes [7,8]. More-
over, proteases of neutrophilic origin such as neutrophil elastase
have been regarded to be important in degradation of surfactant
proteins, epithelial cell apoptosis, and coagulation [9,10]. In
addition, neutrophils produce vast quantities of reactive oxygen
(ROS) and nitrogen (RNS) species like O2
N 2 and NO N through
their oxidant-generating systems such as the phagocyte NADPH
oxidase and nitric oxide synthase (NOS), respectively. Besides their
important antimicrobial effector function, neutrophil-derived
oxidants promote deleterious pro-inflammatory effects thus being
a major cause of neutrophil-dependent tissue injury in ALI [4].
Although a large body of evidence indicates the importance of
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neutrophils in ALI, it should also be pointed out that ALI or acute
respiratory distress syndrome (ARDS) can also occur in patients
with neutropenia [11,12].
Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase, are a class of drugs used for their lipid-
lowering effects and thereby preventing cardiovascular disease.
However, recent studies have revealed anti-inflammatory
pleiotropic effects and plaque stabilizing effects of statins [13].
Their beneficial effects cannot entirely attribute to reduction of
lipid levels [14,15]. Studies on the effect of statins in ALI have
repeatedly shown attenuation of vascular leakage various models
of ALI [16,17], an effect predominantly attributed to endothe-
lium-protecting effects of statins. However, with the importance
of neutrophils in ALI and in regulation of vascular permeability
[18], we here investigate effects of statins on neutrophil
function.
Although previous in vitro and in vivo studies have revealed the
beneficial effects of statins in ALI, little is known about the effects
of statins on neutrophils in ALI. Beside the beneficial effect of
lovastatin in acute lung injury, Fessler et al. revealed impaired host
defence due to inhibitory effects on Rac activation, actin
polymerization, chemotaxis, and bacterial killing of neutrophils
isolated from lovastatin-treated mice [19]. Recruitment of
neutrophils, release of granule proteins and generation of ROS
by neutrophils display key events in ALI and may represent
a potential target for therapy. Consequently, we address the effect
of simvastatin treatment on ALI and on neutrophil effector
functions.
Methods
Animals
Male C57Bl/6 mice, 8 weeks of age, were obtained from Janvier
(Elevage Janvier, Le Genest St. Isle, France). Neutrophils were
depleted by intraperitoneal injection of monoclonal antibody 1A8
(100 mg per mouse 12 hours and 0 hours before Lipopolysaccharid
(LPS) inhalation, BioXcell, West Lebanon, N. Hamp.). Mice were
treated with simvastatin (2 mg/g bodyweight) or NaCl 0.9% by
intraperitoneal injection 12 hours and 0 hours before LPS
inhalation or 1 hour after LPS inhalation, respectively. The
experiments were officially approved by the state office for nature,
environment and consumer protection Cologne, Germany (Land-
esamt fu¨r Natur, Umwelt und Verbraucherschutz Ko¨ln, AZ 87-
51.04.2010.A268). All animals received humane care in accor-
dance with the requirements of the German Animal Protection
Act (Tierschutzgesetz), 18 Article 1 and in accordance to the
Guide for the Care and Use of Laboratory Animals published by
the German National Institute of Health.
Murine Model of Acute Lung Injury
Murine model of ALI was performed as described previously
[20,21]. Aerosolized LPS from Salmonella enteritidis (Sigma Co., St.
Louis, MO) dissolved in 0.9% saline (500 mg/ml) was utilized to
induce neutrophil-infiltration in the lung. Six mice were exposed
simultaneously to aerosolized LPS in a custom-built box (22 cm
in length; 10 cm in diameter) connected to an air nebulizer
(MicroAir, Omron Healthcare, Vernon Hills, IL) for 30 minutes.
Control mice were exposed to saline aerosol. Neutrophil counts
in bronchoalveolar lavage (BAL) and lung tissue (interstitium and
pulmonary vasculature) were assessed 4 hours after inhalation.
30 min before euthanasia, 5 ml FITC-Ly-6G anti-mouse
(eBioscience) labeling intravascular neutrophils and 100 ml
Fluorescein isothiocyanate-Dextran (30 mg/ml FITC-Dextran;
70 kDa, Sigma-Aldrich) were applied by tail vein injection. The
mice were anesthetized with an intraperitoneal injection of
ketamine (125 mg/kg body weight; Sanofi-Cefa GmbH Du¨ssel-
dorf, Germany) and xylazine (12.5 mg/kg b.w.; Phoenix
Scientific). The trachea was dissected and cannulated (PortexFi-
neBore Polythene Tubing, 0.28 mm inner diameter (ID)/
0.61 mm outer diameter (OD), Smiths Medical International,
Keene, NH). 560.5 ml PBS was injected and withdrawn.
Thereafter, the ribcage was opened by a midline incision and
the pulmonary vasculature was rinsed with 15 ml ice-cold PBS
with 0.5 mM EDTA after cutting the inferior cava vein to
facilitate exsanguination. The lungs were removed, minced and
digested with Liberase (1:20; 25 mg Liberase RI/ml aqua, Roche
Mannheim Germany). Digested lungs were passed through a cell
strainer (70 mm; MiltenyiBiotec GmbH, Bergisch Gladbach,
Germany) and the resulting single cell suspension was centrifuged
for 5 min at 300 g. The pellets were resuspended in 1 ml hank’s
balanced salt solution with 0.3 mmol/l EDTA and 0.1% BSA.
The bronchoalveolar lavage (BAL) fluid was centrifuged for
5 min at 300 g (Figure S1).
Flow Cytometry
Cell pellets were labeled with PerCP-Cy5.5 anti-mouse Ly-6G,
PE anti-mouse CD115, APC-Cy7 anti-mouse CD45 und APC
anti-Mouse F4/80 (all eBioscience). Neutrophils were identified by
their typical appearance in the forward scatter-side scatter and as
CD45+ CD115– and PerCP- Gr1+ cells (Figure S2). Within the
lung, FITC-Gr1 antibody was used to distinguish between
interstitial neutrophils (CD45+, CD115–, PerCP- Gr1+, FITC-
Ly6G -) and intravasal neutrophils (CD45+, CD115–, PerCP-
Gr1+, FITC-Ly6G +) as described previously [20,22]. All studies
were performed on a FACS Canto II (Becton Dickinson, San Jose,
CA) and data were analyzed using FlowJo software (Tree Star,
Ashland, OR).
Lung Permeability
FITC-Dextran (70 kDa, Sigma-Aldrich) was used to assess
vascular leakage. 100 ml FITC-Dextran (30 mg/ml) were admin-
istered by tail vein injection 30 min prior to euthanasia and dye
extravasation was used to assess change in vascular permeability.
The fluorescence of the 100 ml BAL supernatant (FluoBAL) and of
50 ml serum (FluoSerum) was measured and permeability volume
was expressed in microlitre (VPerm= (FluoBAL/100 ml)/(FluoSerum/
50 ml) * BAL volume) [20,21].
Albumin Concentration of the BAL
The albumin content of the BAL supernatants was assessed
using ELISA Kit for Albumin (E91028Mu Uscn Life Science
Wuhan China). Measurement of absorbance at 450/540 nm was
performed with a microplate reader (infinite 200,Tecan Group
Switzerland).
Elastase Acitivity
Elastase activity was measured using the Molecular Probes’
EnzChekH Elastase Assay Kit (E-12056 Molecular Probes Europe,
Leiden, The Netherlands). Measurement of absorbance at 515 nm
was performed with a microplate reader (infinite 200,Tecan
Group Switzerland).
Histology and Electron Microscopy
After completion of the experiment, one part of the right lung
was fixed in formalin, embedded in paraffin wax and stained with
Mayer’s haematoxylin and eosin for histological examination.
Another part of the lung was prepared for scanning electron
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microscopy as described [6]. We scored histological sections based
on a scheme outlined in a recent report from the American
Thoracic Society outlining standardized guidelines for models of
ALI in animals [23].
Neutrophil Isolation
Human neutrophils were isolated and purified from venous
blood of healthy donors by density gradient centrifugation using
PolymorphprepTM system (Axia-Shield, Fisher-Scientific,
Schwerte Germany). 20.0 ml of EDTA-anticoagulated whole
blood was layered over 20 ml of PolymorphprepTM in a 50 ml
centrifuge tube. Centrifugation (450–5006g for 30–35 minutes
in a swing-out rotor at 18–22uC) resulted in separation with two
leucocyte bands visible, whereof the lower one represented the
neutrophils. Polymorphonuclear cells were washed and resus-
pended in culture medium (RPMI Medium invitrogen) [24].
Degranulation
After incubation with Simvastatin, neutrophils were activated
by adding 10 mM fMLP (N-Formylmethionyl-Lencyl-Phenylala-
nin) (Sigma) and upregulation of CD11b, CD29 and FPRL1 was
measured after 30 min using FACS Canto II.
Flow Chamber
We coated petri dishes with fibronectin or ICAM1 (1 mg/ml
+10% BSA) for laminar flow chamber. Neutrophils were treated
with Simvastatin (1 mM or 10 mM for 3 hour respectively). After
activation with 10 mM fMLP (Sigma), neutrophils were perfused at
1 dyne/cm2 over fibronectin or ICAM1 and firmly adherent
neutrophils were quantified after 4 min in multiple fields (at least 6
fields, 1006magnification).
Reactive Oxygen Species
ROS was detected by dihydrodichlorofluoresceindiacetate
(DCF, Molecular Probes, Eugene, OR USA) as described
previously [25]. Basically, cells were incubated with the profluor-
escent, lipophilic H2-DCF-DA which can diffuse through the cell
membrane. Reaction with intracellular ROS results in the
fluorescent molecule DCF (max. emission ,530 nm), so that
DCF fluorescence can be used as a measure for intracellular ROS
levels. Fluorescence intensity was quantified with FACS Canto
every 10 min over 1 hour.
Bacterial Killing
After incubation of neutrophils with simvastatin, neutrophils
were incubated with E. coli (BL21). After 20 min, neutrophils were
disrupted by alkaline lysis (H2O with NaOH at pH 14). Viable
bacteria were then grown on Luria Bertani agar over night and the
colonies enumerated.
Phagocytosis
Fluorescent E. coli and opsonizing reagent (Molecular Probes)
were reconstituted as indicated by the manufacturer. IgG
opsonization was achieved according to the manufacturer’s
instructions. Complement opsonization was attained by incubation
of bacteria with fresh human serum at 37uC for 1 hour. Opsonized
particles were washed and seeded onto neutrophils which had
been incubated with Simvastatin (1 mM or 10 mM) for 3 hours.
Neutrophils were activated by adding 10 mM fMLP. Fluorescence
was measured with FACS Canto (Becton Dickinson, San Jose, CA)
after 60 min.
Apoptosis
After incubation with simvastatin, apoptosis of isolated
neutrophils were was measured using Annexin V Kit (Annexin
V Apoptosis Detection Kit I Cat.nr. 556570 BD). Neutrophils
were resuspended in Annexin V binding buffer and stained with
FITC-conjugated Annexin V antibody (BD Pharmingen Cat. Nr.
556419). After 15 minutes PerCP Cy7 conjugated 7-Aminoacti-
nomycin (7AAD) (BD Pharmingen Cat.Nr. 559925) was added to
distinguish between apoptotic and necrotic cells. Apoptosis was
assessed after 3 hours and 24 hours by FACS analysis.
In vivo Analysis of Degranulation after LPS Inhalation
LPS inhalation and sample preparation (BAL and lung) was
done as described above. Degranulation was measured by Flow
cytometry. Cell pellets were labeled with PerCP-Cy5.5 anti-mouse
Ly-6G, PE anti-mouse CD115, APC-Cy7 anti-mouse CD45 und
APC anti-Mouse Ly- 6G (all eBioscience) and FITC anti-mouse
CD29 (Miltenyi Biotec). Neutrophils were identified by their
typical appearance in the forward scatter-side scatter and as
CD45+ CD115– and PerCP- Ly-6G + cells. Within the lung, APC
Ly-6G antibody was used to distinguish between interstitial
neutrophils (CD45+, CD115–, PerCP- Gr1+, APC-Ly6G -) and
intravascular neutrophils (CD45+, CD115–, PerCP- Gr1+, APC -
Ly6G +).
In addition blood was withdrawn by retro orbital puncture 4 h
after LPS inhalation respectively. 100 ml EDTA-blood was lysed
for 15 min using lysing buffer. Cell pellets were labeled with
PerCP-Cy5.5 anti-mouse Ly-6G, PE anti-mouse CD115, APC-
Cy7 anti-mouse CD45 und APC anti-Mouse CD11b (all
eBioscience) and FITC anti-mouse CD29 (Miltenyi Biotec).
Degranulation of neutrophils were measured using FACS Canto
(Becton Dickinson, San Jose, CA).
In vivo Analysis of Bacterial Clearance
Cecal ligation and puncture (CLP) was conducted as described
previously [3,20]. After 24 hours, the mice were sacrificed with an
intraperitoneal injection of ketamine (500 mg/kg body weight;
Sanofi-Cefa GmbH Du¨sseldorf, Germany) and xylazine (50 mg/
kg b.w.; Phoenix Scientific). The lungs were removed, harvested.
The supernatant of the lungs (10 ml and 50 ml) were spread on
Luria Bertani agar over night and the colony forming units (CFU)
were enumerated. Mice were treated with simvastatin (2 mg/g
bodyweight) or NaCl 0.9% by intraperitoneal injection 0 hours
and 12 hours after CLP. In addition, we conducted a midline
laparotomy without cecal ligation and puncture in the control
group (sham operation).
Statistics
All data are expressed as mean 6 standard deviation. Statistical
calculations were performed using GraphPad Prism 5 (GraphPad
Software Inc.). ANOVA, unpaired Student’s t-test, or Kruskal-
Wallis test with posthoc Dunn tests, Bonferroni post tests or
Newman-Keuls Multiple Comparison test were used as appropri-
ate. * indicates a p-value ,0.05.
Results
Protective Role of Simvastatin Treatment Pre and Post
Inducing ALI
LPS-inhalation increased the number of intravascular, in-
terstitial, and alveolar neutrophils as analyzed by flow cytometry
of lung homogenates and BALF (Fig. 1 A and Figure S2).
Furthermore, the albumin concentration as well as the clearance
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Figure 1. Simvastatin reduces LPS-induced acute lung injury by interference with neutrophil recruitment. Mice were challenged with
LPS via inhalation and sacrificed 4 hours later. In addition, neutrophils were depleted by antibody injection or mice were treated with simvastatin
(2 mg/g bodyweight) 12 hours and one hour before or one hour after LPS exposure as indicated. A: Quantification of alveolar (top), interstitial
(middle), and intravascular neutrophils (bottom) in mice treated as indicated. B: FITC-dextran clearance (top), albumin concentration (middle), and
elastase activity (bottom) in BAL fluids in mice treated as indicated (n = 8–10 for each bar). Statistical significance was tested using one way ANOVA
with Newman-Keuls Multiple Comparison test. * indicates significant difference compared to LPS-treated animals.
doi:10.1371/journal.pone.0038917.g001
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volume of the fluorescent dextran increased in the BALF by LPS
treatment indicating enhanced plasma leakage and edema
formation. Moreover, the activity of neutrophil-derived elastase
was elevated in LPS-treated animals (Fig. 1B). The role of
neutrophils in LPS-mediated ALI was assessed by selective
depletion of neutrophils by antibody injection [26]. In line with
the previously reported importance of neutrophils in ALI [4], we
found that neutrophil depletion abolishes permeability increases,
elastase accumulation (Fig. 1B), and structural changes induced by
LPS (not shown).
Simvastatin treatment pre or post has the same impact in LPS-
induced ALI as removing neutrophils. By treatment at either time
point, neutrophil adhesion as well as interstitial and alveolar
infiltration were largely abolished (Fig. 1A). Furthermore,
simvastatin treatment reduced LPS-induced permeability changes
to a degree similar to what was observed by neutrophil depletion
(Fig. 1B) suggesting that simvastatin primarily acts via modulating
neutrophil function. Finally, simvastatin treatment blocked accu-
mulation of neutrophil elastase in the BALF (Fig. 1B).
Histological and ultrastructural analyses of lungs following LPS
exposure revealed alveolar septal thickening, accumulation of
inflammatory cells in the interstitium and the alveoli, and influx of
protein-rich fluid into the alveolar space as compared to control
mice exposed to aerosolized NaCl 0.9% (Fig. 2). In addition,
simvastatin both before (Fig. 2) and after LPS inhalation (data not
shown) reduced structural changes provoked by LPS exposure.
Figure 2. Simvastatin prevents LPS-induced structural changes in the lung tissue. Representative histological (left) and scanning electron
microscopic (right) images of lungs from mice treated as indicated. Scale bars indicate 50 mm for scanning electron microscopy and 250 mm for
histology. Quantification of histological lung sections (bottom) (n = 4 for each bar). Statistical significance was tested using ANOVA with Newman-
Keuls Multiple Comparison test. * indicates significant difference compared to LPS-treated animals.
doi:10.1371/journal.pone.0038917.g002
Figure 3. Simvastatin impairs neutrophil adhesion. Isolated human neutrophils were pre-treated with simvastatin (3 hours, 1 or 10 mM) and
then activated with fMLP. Neutrophils were perfused over immobilized recombinant ICAM-1 or fibronectin at 1 dyne/cm2 and the number of
adherent cells was enumerated. n = 8–10 for flow chamber experiments (repetition of the experiment = 4). Statistical significance was tested using
one way ANOVA with Newman-Keuls Multiple Comparison test.* indicates significant difference of fMLP treated samples compared to each other
samples.
doi:10.1371/journal.pone.0038917.g003
Effect of Statins on Neutrophils
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Simvastatin Reduce Adhesion of Neutrophils to ICAM-1
and Fibronectin
To analyze the effect of simvastatin treatment on neutrophils,
we treated isolated human neutrophils with simvastatin prior to
perfusion over immobilized ICAM-1 (Fig. 3A) or fibronectin
(Fig. 3B). Treatment of neutrophils with simvastatin for 3 hours
(Fig. 3) at 1 or 10 mM severely diminished adhesion to either
substrate indicating a direct effect on neutrophil adhesive
functions.
Simvastatin Reduces fMLP Induced ROS Formation of
Neutrophils
We investigated the effect of simvastatin on ROS formation
induced by fMLP, a secretagogue shed from bacterial walls. fMLP
clearly induced formation of ROS over time (Fig. 4). Pretreatment
of neutrophils with simvastatin for 3 hours abolished ROS
formation.
Effect of Simvastatin on Degranulation of Neutrophils
Degranulation of neutrophils can be assessed by detection of
secreted proteins or by FACS analysis of receptors incorporated
into the cell membrane after granule discharge [27]. Here we went
for the latter approach and investigated the upregulation of
CD11b, CD29, and FPRL1 from intracellular stores following
stimulation with fMLP (Fig. 5A–C). Treatment in this way
significantly enhanced surface expression of all molecules.
However, simvastatin failed to significantly reduce the effect of
fMLP. Nevertheless, there was a trend to reduced expression of
FPRL1 and CD11b. Similar data were also found in preliminary
experiments where MPO and neutrophil elastase were assessed in
the supernatant of activated and simvastatin treated neutrophils
(data not shown).
To assess neutrophil-degranulation in vivo, we assessed neutro-
phil CD11b and CD29 expression after LPS inhalation. LPS
inhalation induced a significant increase of both receptors on
circulating neutrophils (Fig. 5D). However, their expression was
not affected in mice treated with simvastatin (Fig. 5D). In
interstitial lung neutrophils, however, simvastatin treatment
allowed for a trend towards reduced expression of CD11b and
CD29 (Fig. 5E).
Simvastatin does not Impair Neutrophil Bacterial Killing
To analyze negative anti-inflammatory effects of simvastatin we
tested the capacity of simvastatin-treated neutrophils to phagocy-
tose and clear bacteria. Compared to IgG-opsonization, comple-
ment-opsonization increased bacterial uptake (Fig. 6A). With igG
opsonization bacterial uptake was increased following fMLP
exposure. Simvastatin had no effect on the uptake of IgG- or
complement-opsonized bacteria by activated or resting neutrophils
(Fig. 6A). Finally, we investigated the ability of simvastatin to clear
bacteria using a bacterial killing assay. To this end, neutrophils
were allowed to phagocytose living E. coli (BL21) and clearance
was assessed after alkaline lyses and subsequent enumeration of
colony forming units (Fig. 6B).
To further test the impact of simvastatin treatment on bacterial
clearance we induced sepsis by cecal ligation and puncture (CLP).
After 24 hours lungs were collected, homogenized and colony
forming units (CFU) following culture on LB agar over night were
enumerated. As we did not observe increases in CFUs in mice
receiving simvastatin (Fig. 6C), we conclude that simvastatin does
not negatively impact on bacterial clearance.
Simvastatin does not Affect Neutrophil Apoptosis
In addition, we analyzed in vitro neutrophil apoptosis in
presence of simvastatin. In these experiments simvastatin had no
effect on neutrophil apoptosis at 3 or 24 hours independently of
the concomitant presence of fMLP (Fig. 7).
Discussion
Despite all innovation in the intensive care, acute lung injury
induced by Gram-negative bacteria is still an unsolved problem.
Recruitment of neutrophils is a key event in development of ALI
Figure 4. Simvastatin blocks ROS formation in neutrophils. Isolated human neutrophils were pre-treated with Simvastatin (3 hours, 1 or
10 mM), stained with ROS-sensitive H2-DCFDA and then activated with fMLP. In addition, neutrophils were pre-treated with simvastatin as indicated
and fluorescence was measured by flow cytometry FACS Canto (Becton Dickinson, San Jose, CA) every ten minutes following fMLP stimulation. n = 6
for each group; repetition= 4. Statistical significance was tested using one way ANOVA with Newman-Keuls Multiple Comparison test. * indicates
significant difference in comparison to the control group at each different time point.
doi:10.1371/journal.pone.0038917.g004
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[1,4] linking to plasma leakage and deterioration of oxygenation.
The importance of neutrophils in ALI is supported by studies
where lung injury is abolished or reversed by depletion of
neutrophils [5,6]. Much of the neutrophil-dependent ALI is
mediated by neutrophil recruitment, ROS release, and granule
proteins discharge from activated neutrophils. Hence, treatment of
ALI should address the recruitment and degranulation of
neutrophils. Although, there is already evidence of the beneficial
role of statins in sepsis and ALI, there is little known about the
effect of statins on neutrophils.
LPS inhalation mimics human Gram-negative ALI, inducing
neutrophil recruitment, pulmonary edema and finally impairment
of gas exchange [3]. In our study, we confirmed the causative role
of neutrophils in LPS-induced ALI, because neutrophil depletion
reduced plasma leakage und histological signs of lung injury.
Whereas recent studies showed the beneficial effect of simvastatin
treatment before ALI [16,17], our study revealed the same
beneficial effect of statins which were administered after inducing
ALI. Hence, these results highlighted the clinical relevance of
statin therapy which is at present only supported by small clinical
trials [28].
Different mechanisms of endothelial barrier protection by
statins have been reported. Endothelial junctions are stabilized
due to inhibition of RhoA/Rho kinase pathways [29–31]. Beside
this protection of endothelial barrier, simvastatin might directly
reduce the activation and recruitment of the neutrophils which
contribute to the tissue damage in acute lung injury [4].
Consequently, we analyzed the effects of simvastatin on neutrophil
activity. The importance of neutrophil infiltration in LPS-induced
ALI is substantiated in models, where neutrophil adhesion or
migration is impaired. In this context it was shown that lack of
CXCR2 or blockade of b2-integrins protects from ALI [32,33]. In
our hands, simvastatin prevents intravascular neutrophil adhesion
and lung infiltration. As this was recapitulated in an in vitro assay in
absence of other cell types but in presence of substrates typically
involved in neutrophil adhesion and migration we conclude that
the in vivo effects may to a large part relate to direct interference
with neutrophil effector functions.
Although the release of ROS displays an important anti-
microbicidal mechanism, overproduction of ROS can cause
tissue damage in sepsis and ALI [34]. In animal models of ALI,
neutrophil-derived ROS caused lung injury as shown by
histological examination and permeability measurements
[35,36]. In addition, it was evidenced that ROS can disrupt
intercellular tight junctions of the endothelium by phosphoryla-
tion of focal adhesion kinase [37]. Hence, deficiency or blockade
of NADPH oxidase prevents from ALI [38–40]. Here we show
that simvastatin effectively prevents neutrophil ROS production
Figure 5. Influence of simvastatin on neutrophil degranulation in vitro (A–C) and in vivo (D+E). Isolated human neutrophils were pre-
treated with Simvastatin (3 hours, 1 or 10 mM) and then activated with fMLP. MFI of surface expression of CD11b (A), CD29 (B) and FPRL1 (C) as
measured by flow cytometry after staining with directly conjugated antibodies (n = 3–6; repetition = 4). D+E In vivo degranulation after LPS
inhalation. Mice were challenged with LPS via inhalation and sacrificed 4 hours later. After isolation of neutrophils from the blood and the lung, MFI of
surface expression of CD11b and CD29 as measured by flow cytometry after staining with directly conjugated antibodies (n = 4–6). Statistical
significance was tested using one way ANOVA with Newman-Keuls Multiple Comparison test. * indicates significant difference in comparison to the
fMLP or the LPS group.
doi:10.1371/journal.pone.0038917.g005
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which may at least in part explain beneficial effects of simvastatin
in ALI shown here. Consistently, studies demonstrated reduced
activation of NADPH oxidase by statins in endothelium and
macrophages resulting in reduced release [14,29]. The two most
important findings of this study leading to diminished ALI
following statin treatment are reduced neutrophil adhesion and
recruitment as well as decreased ROS production. It has
previously been shown that statins inhibit small GTPases such
as Rho and Rac1 which may serve as mechanistic explanation
for our findings [41,42]. On the one hand, Rho activity is
important in cytoskeletal re-arrangement and as such involved in
leukocyte adhesion and emigration [43]. On the other hand,
statins were shown to block Rac1. Rac1 binds to p67phox and
leads to activation of the NADPH oxidase system and subsequent
generation of ROS [42].
After activation, simvastatin did not significantly ameliorate the
degranulation of neutrophils. The expression of CD11b was
reduced after pretreatment with simvastatin, but without statistical
significance. In accordance to our results, recent studies showed
reduced CD11b expression and inhibition of CD11b-dependent
monocyte adhesion to endothelium by HMG-CoA reductase
inhibitors [44] Similarly, atorvastatin treatment led to a signifi-
cantly lower expression of CD40L, CD11b and CD54 on
monocytes and neutrophils in patients with coronary heart disease
[45]. In a M1 protein induced ALI, simvastatin reduced pro-
duction of CXC chemokines in the lung as well as up-regulation of
CD11b on circulating neutrophils [46]. CD11b and FPRL1 are
stored in secretory vesicles, a subset of neutrophil granules easily
mobilized after neutrophil activation. Following discharge of this
compartment, both receptors are incorporated in the cell
membrane, while soluble mediators are released. Azurocidin
a protein enriched in secretory vesicles is a potent mediator of
neutrophil-derived permeability changes and has previously been
suggested to be involved in septic lung edema formation [7,47].
Hence, the trend towards reduced discharge of secretory vesicles in
our study may together with effects on ROS formation provide an
explanation for reduced permeability changes in simvastatin-
treated mice.
Further to emigration, neutrophils are irreplaceable in
bacterial clearance, much of which is mediated by phagocytosis
and intracellular bacterial killing [48]. In our hands these
functions were not negatively affected by presence of simvasta-
tin. Consistently, it has recently been shown that statins
promote release of neutrophil extracellular traps [49], a scaffold
for catching and killing bacteria. Hence, the lack of adverse
antimicrobial side effects confirms the potential capacity of
statins in clinical settings of bacterial ALI. However, in contrast
to our results, Fessler et. al. showed negative effects of lovastatin
on pulmonary antibacterial host defense after intratracheal
instillation of Klebsiella pneumonia [19]. These divergent results
may caused by using different models of bacterial infection.
Whereas we induced sepsis and lung infection by cecal ligation
and puncture (CLP), Fessler et. al. used a direct intratracheal
instillation of K. pneumonia. Moreover, the different used
inhibitors of HMG-CoA reductase may also display effects with
different intensity. Therefore, transfer of these results to clinical
setting has to be done cautiously. However, the majority of the
clinical studies revealed an increasing evidence that statins have
a beneficial effect on the outcome of infection in humans
without disturbed host defense [15].
Figure 6. Simvastatin does not affect neutrophil antimicrobial activity in vitro (A + B) and in vivo (C). A:Bacterial uptake of fluorescent
IgG- or complement-opsonized E. coli by activated or resting neutrophils as assessed by flow cytometry. Neutrophils were activated with fMLP and
pretreated with simvastatin as indicated n= 4; repetition= 4. Statistical significance was tested using two way ANOVA with with Bonferroni posttest. *
indicates significant difference to the control group without fMLP. B: Formation of colony forming units (CFU) after hypotonic lysis of neutrophils that
had phagocytozed E. coli (BL21) for 20 min. (n = 4). C No negative effect on neutrophil bacterial clearance in acute lung injury. 24 h after cecal ligation
and puncture (CLP), the supernatant of the harvested lungs was spread out on Luria Bertani agar over night and the colony forming units (CFU) were
enumerated. The CFU did not increase after simvastatin treatment in comparison to the CLP group indicating no negative effect on the bacterial
clearance (n = 5). Statistical significance was tested using one way ANOVA with Newman-Keuls Multiple Comparison test. * indicates significant
difference to the control group without neutrophils.
doi:10.1371/journal.pone.0038917.g006
Effect of Statins on Neutrophils
PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e38917
Conclusion
Simvastatin reduces recruitment and activation of neutrophils in
a model of acute lung injury and hereby displays beneficial effects.
Moreover, Simvastatin treatment early after LPS inhalation was
protective implicating a potential role for statins in the prevention
of ALI.
Supporting Information
Figure S1 Experimental outline.
(TIF)
Figure S2 Gating strategy for compartment-specific
identification of neutrophils. A: Neutrophils in the BAL of
ctrl mice or LPS treated mice are identified as CD45+ CD115+
Ly6G+. B: Intravascular (IV) neutrophils are discriminated from
interstitial (IS) neutrophils by being positive for a FITC conjugated
antibody to Ly6G that was injected i.v. 30 minutes before mice
were sacrificed.
(TIF)
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